Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 619-624

  Madlambayan, Gerard J ^a,b   Bartee, Eric ^a   Kim, Manbok ^a,c   Rahman, Masmudur M ^a   Meacham, Amy ^a   Scott, Edward W ^a   McFadden, Grant ^a   Cogle, Christopher R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b OAKLAND UNIVERSITY   (United States)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Animal models; Bone marrow; Hematopoietic stem cell; Leukemia; Oncolytic virotherapy

Indexed keywords

ONCOLYTIC VIRUS;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; GRANULOCYTIC SARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYXOMATOSIS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TUMOR ENGRAFTMENT; TUMOR VOLUME; VIRUS CELL INTERACTION;

ANIMALS; CELL LINE, TUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MYXOMA VIRUS; ONCOLYTIC VIROTHERAPY; SARCOMA, MYELOID;

EID: 84862794917     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.01.020     Document Type: Article

References (22)

1. Kelly E., Russell S.J. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007, 15:651-659.
2. Rahman M.M., Madlambayan G.J., Cogle C.R., McFadden G. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with myxoma virus. Cytokine Growth Factor Rev 2010, 21:169-175.
3. Kirn D.H., Thorne S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009, 9:64-71.
4. Hammill A.M., Conner J., Cripe T.P. Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer 2010, 55:1253-1263.
5. Yu W., Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007, 7:141-148.
6. Bais S., Rahman M., McFadden G., Cogle C. Oncolytic virotherapy for hematologic malignancies. Adv Virol 2012.
7. Thirukkumaran C.M., Russell J.A., Stewart D.A., Morris D.G. Viral purging of haematological autografts: should we sneeze on the graft?. Bone Marrow Transplant 2007, 40:1-12.
8. Kim M., Madlambayan G.J., Rahman M.M., Smallwood S.E., Meacham A.M., Hosaka K., et al. Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 2009, 23:2313-2317.
9. Johnston J.B., Barrett J.W., Chang W., Chung C.S., Zeng W., Masters J., et al. Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J. Virol 2003, 77:5877-5888.
10. Tomayko M.M., Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989, 24:148-154.
11. Smallwood S.E., Rahman M.M., Smith D.W., McFadden G. Myxoma virus: propagation, purification, quantification, and storage. Curr Protoc Microbiol 2010, Chapter 14: Unit 14A 1. http://onlinelibrary.wiley.com/doi/10.1002/9780471729259.mc14a01s17/full.
12. Macen J.L., Upton C., Nation N., McFadden G. SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 1993, 195:348-363.
13. Au G.G., Lincz L.F., Enno A., Shafren D.R. Oncolytic coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol 2007, 137:133-141.
14. Shafren D.R., Dorahy D.J., Greive S.J., Burns G.F., Barry R.D. Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21. J Virol 1997, 71:785-789.
15. Thirukkumaran C.M., Luider J.M., Stewart D.A., Cheng T., Lupichuk S.M., Nodwell M.J., et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 2003, 102:377-387.
16. Alain T., Hirasawa K., Pon K.J., Nishikawa S.G., Urbanski S.J., Auer Y., et al. Reovirus therapy of lymphoid malignancies. Blood 2002, 100:4146-4153.
17. Peng K.W., Ahmann G.J., Pham L., Greipp P.R., Cattaneo R., Russell S.J. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001, 98:2002-2007.
18. Myers R.M., Greiner S.M., Harvey M.E., Griesmann G., Kuffel M.J., Buhrow S.A., et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007, 82:700-710.
19. Parato K.A., Senger D., Forsyth P.A., Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005, 5:965-976.
20. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000, 6:821-825.
21. Boshkov L.K., Macen J.L., McFadden G. Virus-induced loss of class I MHC antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus. J Immunol 1992, 148:881-887.
22. Cattaneo R., Miest T., Shashkova E.V., Barry M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008, 6:529-540.